TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17949722

Group type: EXPERIMENTAL
Intervention: n Power (implicit power motivation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: n Power with contest outcome (win vs. loss)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: n Power in power-motivated winners
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: n Power and estradiol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Self-reported dominance and aggression
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: n Power
Number of subjects: 49
Study: 16243090

Group type: EXPERIMENTAL
Intervention: Dimethoate
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Fenthion
Number of subjects: 802

Group type: COMPARATOR
Intervention: Chlorpyrifos
Number of subjects: 802
Study: 12067837

Group type: COMPARATOR
Intervention: Insulin infusion alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin plus lipid/heparin infusion
Number of subjects: 16
Study: 10661828

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8886540

Group type: EXPERIMENTAL
Intervention: Ketoconazole 0.5 percent shampoo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ketoconazole 1 percent shampoo
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 78
Study: 1898641

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) therapy
Number of subjects: 376
Study: 6306038

Group type: EXPERIMENTAL
Intervention: CRF (0.3 micrograms/kg BW)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CRF (3 micrograms/kg BW)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CRF (30 micrograms/kg BW)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30121470

Group type: EXPERIMENTAL
Intervention: DNA methylation (DNAm) in blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration between social scientists, health methodologists, and basic scientists
Number of subjects: 0
Study: 27930497

Group type: EXPERIMENTAL
Intervention: VPA + DM (30 mg/d)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: VPA + DM (60 mg/d)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 26869049

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m² (reduced to 125 mg/m² after 464 participants)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Solvent-based paclitaxel 80 mg/m²
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Number of subjects: 1206
Study: 25389139

Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (HS) administered 6-hourly
Number of subjects: 317

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (HS)
Number of subjects: 317
Study: 22309791

Group type: EXPERIMENTAL
Intervention: Balloon Analog Risk Task (BART)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hazardous drinking assessment with AUDIT
Number of subjects: 79
Study: 19486466

Group type: EXPERIMENTAL
Intervention: Topical fluoride varnish three times per school year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varnish plus twice‐per‐day toothbrushing and xylitol containing gummy bear snacks
Number of subjects: 0
Study: 17894710

Group type: COMPARATOR
Intervention: 6 J/cm² without CAC
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 6 J/cm² with CAC (level 4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 9 J/cm² with CAC (level 4)
Number of subjects: 11
Study: 16079640

Group type: COMPARATOR
Intervention: Pravastatin, 40 mg daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mild endurance exercise training (three or more times a week)
Number of subjects: 28
Study: 10770301

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin 100 IU/kg subcutaneously twice a day)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Aspirin (160 mg every day)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 449
Study: 9410771

Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VVI mode
Number of subjects: 32

Group type: COMPARATOR
Intervention: DDD mode in patients with retroconduction
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VVI mode in patients with retroconduction
Number of subjects: 32

Group type: COMPARATOR
Intervention: DDD mode in patients without retroconduction
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VVI mode in patients without retroconduction
Number of subjects: 32

Group type: COMPARATOR
Intervention: DVI stimulation during DDD mode
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VDD stimulation during DDD mode
Number of subjects: 32
Study: 8447210

Group type: EXPERIMENTAL
Intervention: P6 acupoint injection with 0.2 ml 50% glucose in water
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 20 micrograms/kg droperidol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 120
Study: 3753988

Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 2908235

Group type: EXPERIMENTAL
Intervention: 30 mg D-fenfluramine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study: 30946442

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 10 mg/kg every 6 hours for the first 9 postoperative days
Number of subjects: 741

Group type: COMPARATOR
Intervention: Acetaminophen, 15 mg/kg every 6 hours for the first 9 postoperative days
Number of subjects: 741
Study: 28138803

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in primary care (PCP)
Number of subjects: 3152

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in specialist care
Number of subjects: 3152

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment in PCP
Number of subjects: 3152
Study: 26173613

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23187164

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (5 mg/mL) 4 times daily for 2 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Artificial tear 4 times daily for 2 months
Number of subjects: 44
Study: 21996108

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Autologous fascial sling
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group (surgical failures)
Number of subjects: 655
Study: 18808333

Group type: EXPERIMENTAL
Intervention: rBCG30
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tice BCG
Number of subjects: 35
Study: 16546766

Group type: EXPERIMENTAL
Intervention: Applied relaxation (7 group sessions over 7 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment as usual (average of 11 individual sessions over 20 weeks)
Number of subjects: 37
Study: 12836580

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT); specific treatment strategies targeting relational ruptures and rebuilding relationships; details on dosage and duration not available.
Number of subjects: 0
Study: 10679658

Group type: COMPARATOR
Intervention: Radiation therapy alone (Arm A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (Arm B)
Number of subjects: 100
Study: 9538431

Group type: EXPERIMENTAL
Intervention: Educational project intervention in nursery schools, involving awareness-raising among families and teaching tools distributed by community physicians over 2 years.
Number of subjects: 1500
Study: 8418228

Group type: EXPERIMENTAL
Intervention: Melphalan/prednisone
Number of subjects: 278

Group type: COMPARATOR
Intervention: Melphalan/prednisone/interferon alfa-2b
Number of subjects: 278
Study: 2430797

Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (2.5 ml in 8% dextrose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyperbaric 0.5% cinchocaine (1.5 ml in 6% dextrose)
Number of subjects: 60
Study: 31266717

Group type: EXPERIMENTAL
Intervention: tRNS (real session)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham session
Number of subjects: 32
Study: 28770527

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Person-centred counselling
Number of subjects: 36
Study: 26426664

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 9256

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 9256

Group type: COMPARATOR
Intervention: Macrolide + β-lactam
Number of subjects: 9256

Group type: EXPERIMENTAL
Intervention: β-lactam alone
Number of subjects: 9256
Study: 23507136

Group type: EXPERIMENTAL
Intervention: Self-completion version of the Clinical Interview Schedule (CIS-R)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Interviewer-administered Clinical Interview Schedule (CIS-R)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Self-completion version of the CIS-R
Number of subjects: 277
Study: 21264830

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 158

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 158
Study: 18287591

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0.05 mg/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (50 microg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acetylcholine chloride (100 microg)
Number of subjects: 57
Study: 16572442

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study: 14583341

Group type: EXPERIMENTAL
Intervention: 4 g daily of purified eicosapentaenoic acid (EPA) for 6 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 4 g daily of docosahexaenoic acid (DHA) for 6 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olive oil (control) for 6 weeks
Number of subjects: 59
Study: 11177158

Group type: EXPERIMENTAL
Intervention: 100 IU/d of recombinant follicle‐stimulating hormone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 200 IU/d of recombinant follicle‐stimulating hormone
Number of subjects: 40
Study: 9226493

Group type: EXPERIMENTAL
Intervention: Palatable meal (Ensure, 1048 KJ, 450 ml)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unpalatable meal (Ensure with aqueous KCl)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Threshold for unpleasant taste of KCl
Number of subjects: 43
Study: 8408914

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Sclerotherapy of reticular veins
Number of subjects: 700
Study: 2878811

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 45

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: both terfenadine and ranitidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: terfenadine and ranitidine
Number of subjects: 45
Study: 29789365

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: AMC (Traditional Chinese Herbal Formula)
Number of subjects: 450
Study: 28147254

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 85
Study: 25572450

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23974915

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus laser
Number of subjects: 345

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 345
Study: 20048683

Group type: COMPARATOR
Intervention: 0.5 g rPC daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 g rPC daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 g rPC daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 g rPC daily
Number of subjects: 40
Study: 18419402

Group type: EXPERIMENTAL
Intervention: HZ vaccine
Number of subjects: 38546
Study: 16612277

Group type: EXPERIMENTAL
Intervention: C0 monitoring of cyclosporine (CsA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: C2 monitoring of cyclosporine (CsA)
Number of subjects: 160
Study: 14562520

Group type: EXPERIMENTAL
Intervention: Interpretive short-term group therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Supportive short-term group therapy
Number of subjects: 107
Study: 11105068

Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8900613

Group type: EXPERIMENTAL
Intervention: Relaxation exercises (progressive muscle relaxation, meditative breathing, guided imagery, soft music)
Number of subjects: 39
Study: 1839644

Group type: EXPERIMENTAL
Intervention: Oral CBD (10 mg/kg/day for 6 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (sesame oil for 6 weeks)
Number of subjects: 15
Study: 6623221

Group type: EXPERIMENTAL
Intervention: Enflurane as a volatile supplement to nitrous oxide anesthesia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Halothane as a volatile supplement to nitrous oxide anesthesia
Number of subjects: 107
Study: 30189282

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 914
Study: 28138958

Group type: EXPERIMENTAL
Intervention: Open left lateral sectionectomy (OLLS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laparoscopic left lateral sectionectomy (LLLS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open non-randomized (ONR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laparoscopic non-randomized (LNR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 24
Study: 26030174

Group type: EXPERIMENTAL
Intervention: Thinking about future selves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking about past selves
Number of subjects: 0
Study: 23473527

Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg BID for 4 weeks, then 10 μg BID for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 50
Study: 22611676

Group type: EXPERIMENTAL
Intervention: Mexidol (100 mg intramuscular for 10 days, then 125 mg orally three times a day for 20 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular treatment (Diroton 5-20 mg daily, Cardiomagnyl 75 mg daily)
Number of subjects: 40
Study: 19256262

Group type: EXPERIMENTAL
Intervention: Creon (25000 U)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Creon (25 or 50% higher dose)
Number of subjects: 32
Study: 17451693

Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian diathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian diathermy
Number of subjects: 0
Study: 15094530

Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercises
Number of subjects: 81

Group type: COMPARATOR
Intervention: Individualized physical therapy without specific stabilizing exercises
Number of subjects: 81
Study: 12964233

Group type: EXPERIMENTAL
Intervention: Hydropolymer dressing
Number of subjects: 113

Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 113
Study: 10214426

Group type: EXPERIMENTAL
Intervention: Group B (treatment group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group A (no treatment)
Number of subjects: 110
Study: 8921786

Group type: EXPERIMENTAL
Intervention: TIMI grade 2 flow at 90 minutes improving to TIMI grade 3 flow at follow-up (5-7 days)
Number of subjects: 914

Group type: COMPARATOR
Intervention: TIMI grade 2 flow at 90 minutes
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Improvement from TIMI grade 2 to TIMI grade 3 flow
Number of subjects: 914

Group type: COMPARATOR
Intervention: Persistent TIMI grade 2 flow
Number of subjects: 914
Study: 2155958

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg, two puffs, four times per day for 12 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (two puffs, four times per day for 12 weeks)
Number of subjects: 188
Study: 7428402

Group type: EXPERIMENTAL
Intervention: 30 mg vincamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31862004

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg loading dose and 30 mg/kg/h continuous maintenance infusion for 1 h (group H)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg loading dose and 15 mg/kg/h continuous maintenance infusion for 1 h (group L)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (0.9% saline infusion)
Number of subjects: 69
Study: 27736113

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus feedback (MIF)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Psychoeducation (control)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Both MIF and control
Number of subjects: 242
Study: 26092195

Group type: EXPERIMENTAL
Intervention: Pleasant, natural sounds via headphones for 90 minutes
Number of subjects: 60
Study: 25227540

Group type: EXPERIMENTAL
Intervention: Segmental muscle vibration (SMV) + exercise (120 Hz SMV over biceps brachii and flexor carpi ulnaris)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Exercise only (Control Group)
Number of subjects: 22
Study: 22170479

Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg/day for 4 weeks (stage 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg/day for 8 weeks (stage 2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg twice a day for 8 weeks (stage 3)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16824688

Group type: EXPERIMENTAL
Intervention: Lung age and respiratory symptoms feedback
Number of subjects: 124

Group type: COMPARATOR
Intervention: Brochure containing facts about smoking
Number of subjects: 124
Study: 15725132

Group type: EXPERIMENTAL
Intervention: 250 mL of terminal warm blood cardioplegia (TWBC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 500 mL of terminal warm blood cardioplegia (TWBC)
Number of subjects: 50
Study: 12034651

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 40 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 80 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Statin-80 (atorvastatin or simvastatin 80 mg/d)
Number of subjects: 50
Study: 9224205

Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study: 8017672

Group type: EXPERIMENTAL
Intervention: Propofol (6-10 mg.kg-1.h-1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone-isoflurane (isoflurane continuously injected)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone-isoflurane (group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 3305743

Group type: EXPERIMENTAL
Intervention: Functioning transcutaneous electrical nerve stimulator
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-functioning transcutaneous electrical nerve stimulator
Number of subjects: 26
Study: 29024230

Group type: EXPERIMENTAL
Intervention: 0.05 mol/L GABA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 mol/L GABA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study: 27623538

Group type: EXPERIMENTAL
Intervention: Education program (lecture followed by group discussion and information booklet)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Information booklet
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 203
Study: 24790012

Group type: EXPERIMENTAL
Intervention: Exercise (ExBR) - rowing ergometry 6 days/week and supplemental strength training 2 days/week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sedentary bed rest (BR)
Number of subjects: 27
Study: 22564503

Group type: EXPERIMENTAL
Intervention: Presentation of study event rates
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Absolute risk differences
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Additional information in table cells
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Time frame information in tables
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Risk differences
Number of subjects: 116
Study: 20608354

Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study: 18551622

Group type: EXPERIMENTAL
Intervention: Arimoclomol at doses up to 300 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Arimoclomol at doses of 25, 50, or 100 mg three times daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16075861

Group type: EXPERIMENTAL
Intervention: Intramuscular clindamycin (outpatient treatment)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous ampicillin/sulbactam (inpatient treatment)
Number of subjects: 58